Mineralys Therapeutics (MLYS) Interest & Investment Income (2022 - 2026)

Mineralys Therapeutics has disclosed Interest & Investment Income across 5 years of filings, most recently posting $6.0 million for Q1 2026.

• Interest & Investment Income for Q1 2026 came in at $6.0 million, up 167.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.7 million (up 51.92% YoY), and the FY2025 annual result was $16.0 million, up 9.36% from the prior year.
• Interest & Investment Income came in at $6.0 million for Q1 2026 at Mineralys Therapeutics, down from $6.0 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $6.0 million in Q4 2025 to a low of $741000.0 in Q3 2022.
• The 5-year median for Interest & Investment Income is $3.5 million (2023), against an average of $3.4 million.
• Across the five-year window, Interest & Investment Income jumped 374.09% in 2023 and slumped 41.89% in 2025, its largest moves.
• Mineralys Therapeutics' Interest & Investment Income stood at $935000.0 in 2022, then soared by 255.19% to $3.3 million in 2023, then fell by 15.42% to $2.8 million in 2024, then surged by 115.2% to $6.0 million in 2025, then dropped by 0.81% to $6.0 million in 2026.
• The last three Interest & Investment Income figures came in at $6.0 million (Q1 2026), $6.0 million (Q4 2025), and $4.2 million (Q3 2025), per Business Quant data.